Bath & Bodyworks Inc. (NYSE: BBWI): This year will be a tough one for its Bear of the Day stock, says Zacks. Shares of the personal care company have traded as high as $58.17 in the past year but closed most recently at $35.36. That is down about 16% year to date.
Camden Property Trust (NYSE: CPT): Goldman Sachs lowered its $134 target price on the Neutral-rated stock to $120. The consensus target is $133.10. The stock closed on Tuesday at $105.95.
CION Investment Corp. (NASDAQ: CION): Wells Fargo’s downgrade to Equal Weight from Overweight included a target price cut from $10.50 to $9.25, the same as the consensus target. The stock closed on Tuesday at $128.73.
Core Laboratories N.V. (NYSE: CLB): BofA Securities downgraded the stock from Neutral to Underperform with a $21.50 target price. The consensus target is $23.19. The stock closed on Tuesday at $22.00.
Danaher Corp. (NYSE: DHR): When Wells Fargo boosted its Equal Weight rating to Overweight, its target price rose to $285 from $275. The consensus target is up at $300.30, and shares closed on Tuesday at $256.14.
Enterprise Products Partners L.P. (NYSE: EPD): The $29 target price at Barclays is now $30, and the firm’s Overweight rating remains. The consensus target is $31.80. The shares closed on Tuesday at $27.01.
Humana Inc. (NYSE: HUM): Jefferies reiterated a Buy rating with a $612 target price. The consensus target is $602.76. Tuesday’s close was at $512.68.
Lear Corp. (NYSE: LEA): BofA Securities hiked its $165 target price to $170 and kept its Buy rating. The consensus target is $162.64. The stock closed at $136.75 on Tuesday.
Lovesac Co. (NASDAQ: LOVE): Oppenheimer reiterated an Outperform rating. Its $60 target price compares with a $52.50 consensus target and Tuesday’s close at $29.87, which was up almost 4% on the day after positive analyst commentary.
Marathon Petroleum Corp. (NYSE: MPC): Wells Fargo’s downgrade to Equal Weight from Overweight came with a target price cut from $153 to $135. The consensus target is $153.00. The stock closed on Tuesday at $129.06.
Merus N.V. (NASDAQ: MRUS): Stifel raised its $34 target price to $44 while keeping a Buy rating. The consensus target is $40.60. Tuesday’s $20.45 close came after a 14% plunge in the wake of clinical data.
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
